Solid Biosciences (SLDB) Stock Statistics & Valuation Metrics

Solid Biosciences has a market cap or net worth of $761.55M. The enterprise value is $563.06M.

Solid Biosciences has 98,391,310 shares outstanding. The number of shares has decreased by -2.65% in one year.

Solid Biosciences’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -89.08%.

The current PE Ratio of Solid Biosciences is ―. Solid Biosciences’s PEG ratio is 0.08.

In the last 12 months, Solid Biosciences had revenue of 0.00 and earned -174.32M in profits. Earnings per share was -1.99.

In the last 12 months, operating cash flow was -156.29M and capital expenditures -1.15M, giving a free cash flow of -157.44M billion.

Solid Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Solid Biosciences upcoming earnings date is May 7, 2026, TBA (Confirmed).

Solid Biosciences as a current ratio of 6.14, with Debt / Equity ratio of 11.76%

In the past 12 months, Solid Biosciences has paid 0.00 in taxes.

Solid Biosciences EV to EBITDA ratio is -2.56, with an EV/FCF ratio of -2.89.

Solid Biosciences has $189.07M in cash and marketable securities with $21.16M in debt, giving a net cash position of $167.91M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Solid Biosciences is $17.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy